The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial.
A. M. L. Lim
No relevant relationships to disclose
D. Rischin
No relevant relationships to disclose
H. Cao
No relevant relationships to disclose
R. Fisher
No relevant relationships to disclose
G. A. McArthur
No relevant relationships to disclose
L. J. Peters
No relevant relationships to disclose
R. J. Young
No relevant relationships to disclose
Q. Le
No relevant relationships to disclose